Who are Porsolt ?

Porsolt, a long established preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 35 years, covering the drug development process from early screening through regulatory submission.

Porsolt provides physiopathological models in multiples species, customized procedures and tailored solutions including in vitro assays and drug formulation analysis and bioanalytical services for :

Porsolt also offers comprehensive safety evaluation of drug candidate from screnning to pre-Phase1 regulatory studies (ICHS7) in full compliance with GLP:

> safety pharmacology

Porsolt has expanded its European laboratory operations in 2011. The new facility (5500 sqm) offers increased capacity for  expanding cross-therapeutic area models and GLP safety pharmacology expertise. The new laboratory will provide the means for sustainable growth over coming years.

In December 2015, Porsolt has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and in vitro screening services. The acquisition further expands Porsolt’s capabilities and services that can assist clients at earlier stages of their drug discovery programs.